Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 11/20 | 0.56 |
| ▸ | CA2 | P00918 | 11/20 | 0.56 |
| ▸ | CA12 | O43570 | 7/20 | 0.56 |
| ▸ | CA9 | Q16790 | 7/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | STK17B | O94768 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6170516 | 0.98 | TDP1 (0.61) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL26641099 | 0.98 | TDP1 (0.61) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL21997325 | 0.98 | TDP1 (0.61) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL5056320 | 0.98 | TDP1 (0.61) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL1057873 | 0.98 | TDP1 (0.61) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL23833687 | 0.98 | TDP1 (0.61) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL7527124 | 0.98 | TDP1 (0.61) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL455207 | 0.95 | TDP1 (0.56) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL5572140 | 0.90 | TDP1 (0.55) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL28520852 | 0.89 | TDP1 (0.46) | TDP1CA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388615-A9 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | ARDELYX, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250250282-A1 | NOVEL SEVEN-MEMBERED RING-FUSED COMPOUNDS | Prism BioLab Co., Ltd. (JP) | 2025-08-07 | — | — | US | disclosed |
| US-12319659-B2 | Selective ligand for dopamine D3 receptor, preparation method therefor, and pharmaceutical application thereof | SHENZHEN LINGLAN BIO-PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) | 2025-06-03 | — | — | US | disclosed |
| US-20250066410-A1 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | ARDELYX, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| US-12084472-B2 | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists | ARDELYX, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-11891558-B2 | Solid foam comprising mesogenic ligand-functionalized nanoparticles and methods of making and using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-02-06 | — | — | US | disclosed |
| CN-110709081-B | Compounds and methods for treating bacterial infections | 恩塔西斯治疗公司 | 2023-09-22 | — | — | CN | disclosed |
| US-11708530-B2 | Organic ligands for templatable mesoscale nanocapsules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-25 | — | — | US | disclosed |
| US-11667621-B2 | Antiestrogen compounds | STEVENS INSTITUTE OF TECHNOLOGY (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667621-B2 | Antiestrogen compounds | STEVENS INSTITUTE OF TECHNOLOGY (US) | 2023-06-06 | — | — | US | disclosed |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090088435-A1 | METHODS AND COMPOUNDS FOR TREATING RETINOL-RELATED DISEASES | SIRION THERAPEUTICS, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| US-20090036431-A1 | Cytotoxic Agents Comprising New Tomaymycin Derivatives | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | US | disclosed |
| US-20090036431-A1 | Cytotoxic Agents Comprising New Tomaymycin Derivatives | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | US | disclosed |
| US-20090036431-A1 | Cytotoxic Agents Comprising New Tomaymycin Derivatives | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | US | disclosed |
| EP-1981889-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | Sanofi-Aventis (FR) | 2008-10-22 | — | — | EP | disclosed |
| US-7365174-B2 | Azalide and azalactam derivatives and method for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-04-29 | — | — | US | disclosed |
| WO-2007085930-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007085930-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-08-02 | — | — | WO | disclosed |
| US-20070042974-A1 | Nozel azalide and azalactam derivatives and method for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066410-A1 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | GPR119, GIPR, GLP1R | TDP1 3907/4885CA1 4826/4885CA2 4604/4885 |
| US-11667621-B2 | Antiestrogen compounds | ESR1, ESR2, ESRRG | TDP1 4202/4885CA1 2479/4885CA2 4146/4885 |
| US-20090088435-A1 | METHODS AND COMPOUNDS FOR TREATING RETINOL-RELATED DISEASES | RBP1, RBP4, ALDH1A2 | TDP1 2387/4885CA1 4831/4885CA2 4250/4885 |
| US-20090036431-A1 | Cytotoxic Agents Comprising New Tomaymycin Derivatives | TOMM70, TOMM34, TOMM40 | TDP1 647/4885CA1 4881/4885CA2 4727/4885 |
| US-20250388615-A9 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | GPR119, GIPR, FFAR3 | TDP1 2943/4885CA1 3827/4885CA2 3648/4885 |
| US-11708530-B2 | Organic ligands for templatable mesoscale nanocapsules | EPCAM, L1CAM, ICOSLG | TDP1 4047/4885CA1 1575/4885CA2 3440/4885 |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | TDP1 2415/4885CA1 4107/4885CA2 3325/4885 |
| US-20070042974-A1 | Nozel azalide and azalactam derivatives and method for producing the same | BCL6, NR4A1, NR4A2 | TDP1 4481/4885CA1 1148/4885CA2 1416/4885 |
| US-20250250282-A1 | NOVEL SEVEN-MEMBERED RING-FUSED COMPOUNDS | NOTCH1, NOTCH2, NOTCH4 | TDP1 4657/4885CA1 3993/4885CA2 3455/4885 |
| US-12084472-B2 | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists | GPR119, GIPR, GLP1R | TDP1 3907/4885CA1 4826/4885CA2 4604/4885 |
| US-12319659-B2 | Selective ligand for dopamine D3 receptor, preparation method therefor, and pharmaceutical application thereof | DRD3, DRD2, PRLHR | TDP1 3035/4885CA1 4824/4885CA2 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.